31.6mg Numelvi Tablets for Dogs - Per Tablet

Description

31.6mg Numelvi contains atinvicitinib, a selective Janus kinase 1 inhibitor, often shortened to a JAK1 inhibitor. It is used to treat pruritus (itching), and the wider skin changes that can come with canine atopy, such as redness, irritation, excoriation from scratching and recurrent flare-ups. Many dogs with allergic skin disease sleep poorly and lick or chew until the skin barrier becomes damaged. 31.6mg Numelvi is intended to help reduce the itch-scratch cycle while your vet also considers the underlying trigger, your dog’s history and any complicating infection.

Allergic dermatitis in dogs occurs when the immune system reacts strongly to something that would not usually cause such a marked response. Common triggers can include environmental allergens such as pollens, house dust mites, mould spores and grasses, as well as flea allergy dermatitis, contact allergy and some adverse food reactions. Atopic dermatitis is a chronic, inflammatory and often genetically influenced form of allergic skin disease in which the skin barrier and immune response are both involved. Dogs with atopic dermatitis may have seasonal signs, year-round signs or a pattern that changes over time.

Typical signs include scratching, chewing the paws, rubbing the face, inflamed ears, recurrent otitis externa, hair loss, scaling, greasy skin, unpleasant odour, saliva staining and sore areas around the feet, muzzle, armpits, groin or belly. Some dogs show mainly ear and paw signs, while others develop widespread erythema, papules or self-trauma, which is why a careful dermatological history and clinical examination are useful before long-term treatment is chosen. 31.6mg Numelvi does not remove the allergen itself, but it can form part of a veterinary plan to control the clinical manifestations of the condition and make the skin more comfortable.

31.6mg Numelvi works by targeting JAK1-dependent signalling pathways used by cytokines, which are small messenger proteins involved in allergy, inflammation and itch. By selectively inhibiting JAK1, Numelvi helps reduce the abnormal signalling that tells the dog’s skin and nervous system to itch and become inflamed. This targeted action is different from simply covering the skin or washing away allergens, because it acts inside the inflammatory pathway that drives many allergic skin signs. The selectivity of 31.6mg Numelvi is clinically relevant because other JAK enzymes are involved in functions such as blood cell production and host defence.

For many dogs, controlling allergic dermatitis is a long-term process. Your vet may recommend regular parasite control, medicated shampoos, ear cleaning, antimicrobial treatment where infection is present, diet trials, essential fatty acids, allergen avoidance where possible or immunotherapy in selected cases. 31.6mg Numelvi can help calm the itch that drives licking, chewing and scratching, but damaged skin still needs time to repair and secondary infections can slow progress if they are not addressed. Owners should avoid changing the dose, combining 31.6mg Numelvi with other systemic immunosuppressive medicines or stopping treatment early without veterinary advice, because flare control is usually tailored to the individual dog. If your dog is waking at night to scratch, chewing paws until they are sore or having repeated ear and skin flare-ups, 31.6mg Numelvi may be one option your vet considers as part of a structured dermatology plan.

Ongoing review is important because canine atopic dermatitis can wax and wane, and a treatment that works well during one season may need adjusting when pollen levels, flea exposure or indoor allergens change. Your vet may use pruritus scores, skin lesion scores, cytology, otoscopic examination and your own observations to judge response to Numelvi over time. You can support treatment by noting when signs flare, checking for new redness or pustules, keeping parasite control up to date and following any bathing or ear-care instructions carefully.

What is 31.6mg Numelvi used for in dogs?
Numelvi is prescribed for dogs with pruritus linked to allergic dermatitis and for clinical signs associated with atopic dermatitis, including itching. It helps reduce the inflammatory signals that make dogs scratch, lick and chew, while your vet investigates triggers such as fleas, environmental allergens, infection or food-related skin disease.

How does Numelvi stop dog itching?
31.6mg Numelvi contains atinvicitinib, a selective JAK1 inhibitor. JAK1 is involved in cytokine signalling, including signals connected with allergy, inflammation and itch. By reducing these signals, the medicine can help calm pruritus and allow irritated skin to become more comfortable alongside wider veterinary skin care.

Is 31.6mg Numelvi the same as Apoquel?
Numelvi and Apoquel are both prescription medicines used for allergic skin disease in dogs, but they contain different active substances. Numelvi contains atinvicitinib, while Apoquel contains oclacitinib. Your vet will choose between treatments based on your dog’s age, weight, diagnosis, medical history and response to previous medication.

What is allergic dermatitis in dogs?
Allergic dermatitis is skin inflammation caused by an allergic reaction. Dogs may react to flea bites, pollens, dust mites, grasses, moulds, contact irritants or sometimes food ingredients. The result can be itching, redness, licking, chewing, hair loss, ear problems and secondary bacterial or yeast infection if the skin barrier becomes damaged.

What is atopic dermatitis in dogs?
Atopic dermatitis is a long-term allergic skin disease involving the immune system and the skin barrier. It often starts in younger dogs and may flare seasonally or persist all year. Common sites include the paws, face, ears, belly, armpits and groin, although signs vary between individual dogs.

What else helps dogs with atopic dermatitis?
Atopic dogs often benefit from a combined plan. This may include parasite control, medicated shampoo, ear care, treatment for bacterial or yeast infection, diet trials, omega oils, allergen reduction and, in selected cases, immunotherapy.